Deutsche Bank AG Takes $1.90 Million Position in Urogen Pharma $URGN

Deutsche Bank AG acquired a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 51,550 shares of the company's stock, valued at approximately $1,897,000. Deutsche Bank AG owned approximately 0.11% of Urogen Pharma at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of URGN. Rice Hall James & Associates LLC purchased a new stake in Urogen Pharma in the 2nd quarter valued at approximately $11,064,000. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma during the 2nd quarter valued at $66,000. Bank of New York Mellon Corp purchased a new position in Urogen Pharma during the second quarter worth $4,159,000. Hennion & Walsh Asset Management Inc. increased its position in Urogen Pharma by 50.8% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 276,696 shares of the company's stock worth $10,182,000 after buying an additional 93,192 shares in the last quarter. Finally, Glenmede Trust Co. NA acquired a new position in shares of Urogen Pharma in the first quarter worth $189,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the company's stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the transaction, the insider owned 59,086 shares of the company's stock, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have sold 85,899 shares of company stock worth $3,747,513. Corporate insiders own 4.80% of the company's stock.

Urogen Pharma Stock Down 4.1%

URGN stock opened at $43.62 on Friday. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81. The stock's fifty day simple moving average is $41.81 and its 200-day simple moving average is $29.95. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -22.03 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts' expectations of $63.55 million. As a group, analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on URGN shares. Oppenheimer upped their price objective on Urogen Pharma from $40.00 to $50.00 and gave the company an "outperform" rating in a research report on Thursday, July 16th. The Goldman Sachs Group reiterated a "neutral" rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research note on Friday, July 17th. UBS Group restated a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, Guggenheim raised their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Urogen Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.38.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source